NEUROCRINE BIOSCIENCES INC's ticker is and the CUSIP is 64125CAD1. A total of 37 filers reported holding NEUROCRINE BIOSCIENCES INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $5,019,203 | -19.2% | 3,168,000 | -28.5% | 0.05% | -22.4% |
| Q3 2022 | $6,210,000 | -1.4% | 4,428,000 | -6.8% | 0.07% | +6.3% |
| Q2 2022 | $6,298,000 | -63.8% | 4,750,000 | -64.1% | 0.06% | -62.9% |
| Q1 2022 | $17,384,000 | +4.8% | 13,230,000 | 0.0% | 0.17% | +9.7% |
| Q4 2021 | $16,595,000 | -5.6% | 13,230,000 | 0.0% | 0.16% | +2.0% |
| Q3 2021 | $17,584,000 | +0.2% | 13,230,000 | 0.0% | 0.15% | +13.4% |
| Q2 2021 | $17,541,000 | -16.3% | 13,230,000 | -14.7% | 0.13% | -24.3% |
| Q1 2021 | $20,948,000 | -52.9% | 15,508,000 | -51.8% | 0.18% | -55.2% |
| Q3 2020 | $44,437,000 | +4.3% | 32,181,000 | +25.7% | 0.40% | -7.7% |
| Q2 2020 | $42,625,000 | +81.6% | 25,595,000 | +40.2% | 0.43% | +25.5% |
| Q1 2020 | $23,476,000 | +7.6% | 18,250,000 | +42.8% | 0.34% | +34.3% |
| Q3 2018 | $21,819,000 | +177.4% | 12,776,000 | +135.2% | 0.25% | +149.0% |
| Q2 2018 | $7,866,000 | – | 5,431,000 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| III Capital Management | 12,500,000 | $17,262,000 | 3.12% |
| CSS LLC/IL | 24,395,000 | $33,616,000 | 1.59% |
| Mint Tower Capital Management B.V. | 9,000,000 | $12,407,000 | 1.46% |
| Context Partners Fund, L.P. | 3,000,000 | $4,125,000 | 0.90% |
| Context Capital Management, LLC | 3,000,000 | $4,125,000 | 0.90% |
| SHENKMAN CAPITAL MANAGEMENT INC | 4,258,000 | $5,971,000 | 0.71% |
| SSI INVESTMENT MANAGEMENT LLC | 5,888,000 | $8,100,000 | 0.70% |
| Aequim Alternative Investments LP | 3,000,000 | $4,155,000 | 0.55% |
| WOLVERINE ASSET MANAGEMENT LLC | 32,181,000 | $44,437,000 | 0.40% |
| TWO SIGMA SECURITIES, LLC | 13,000,000 | $17,875,000 | 0.36% |